Lantus Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

In uncontrolled T2DM treated with a basal-bolus insulin regimen, weekly icodec was noninferior to daily glargine for HbA < sub > 1c < /sub > at 26 wk
Ann Intern Med. 2023 Aug 1. doi: 10.7326/J23-0058. Online ahead of print.ABSTRACTMathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023;401:1929-1940. 37156252.PMID:37523705 | DOI:10.7326/J23-0058 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - July 31, 2023 Category: Internal Medicine Authors: Heiba Belal Gunjan Y Gandhi Source Type: research

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
This article reviews the results of major randomized controlled trials in people with type 2 diabetes that compared iGlarLixi to other therapeutic regimens, representing different intensification strategies, such as basal supported oral therapy, oral antidiabetic drugs, and a combination of the latter with glucagon-like peptide 1 receptor agonists. Moreover, a s a supplement to randomized trials, data from real-world evidence have also been included. (Source: Advances in Therapy)
Source: Advances in Therapy - July 11, 2023 Category: Drugs & Pharmacology Source Type: research

Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study
ConclusioniGlarLixi administration resulted in early absorption of both iGlar and lixisenatide with a good tolerability profile in healthy Chinese participants. These results are consistent with the previously published data from other geographic regions.Trial registrationU1111-1194-9411. (Source: Diabetes Therapy)
Source: Diabetes Therapy - June 17, 2023 Category: Endocrinology Source Type: research

The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of Type 2 Diabetes: A Narrative Review
This article reviews the results of major randomized controlled trials in people with type 2 diabetes that compared iGlarLixi to other therapeutic regimens, representing different intensification strategies, such as basal supported oral therapy, oral antidiabetic drugs, and a combination of the latter with glucagon-like peptide 1 receptor agonists. Moreover, as a supplement to randomized trials, data from real-world evidence have also been included.PMID:37326901 | DOI:10.1007/s12325-023-02567-1 (Source: Adv Data)
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Hanna Kwiendacz Katarzyna Nabrdalik Leszek Czupryniak Tomasz Klupa Maciej Ma łecki Ma łgorzata Myśliwiec Krzysztof Strojek Janusz Gumprecht Source Type: research

Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
Conclusions/interpretationDouble or triple doses of once-weekly icodec lead to a similar risk of hypoglycaemia compared with double or triple doses of once-daily glargine U100. During hypoglycaemia, comparable symptomatic and moderately greater endocrine responses are elicited by icodec vs glargine U100.Trial registrationClinicalTrials.gov NCT03945656.FundingThis study was funded by Novo Nordisk A/S.Graphical Abstract (Source: Diabetologia)
Source: Diabetologia - June 13, 2023 Category: Endocrinology Source Type: research

Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study
ConclusionsIrrespective of the treatment regimen at baseline (insulin vs. OAD only), this patient-level simulation demonstrated that a greater proportion of patients achieved their A1C goals with iGlarlixi compared to iGlar or lixisenatide alone. These findings suggest that the benefits of iGlarLixi extend to clinically distinct RW populations. (Source: Diabetes Therapy)
Source: Diabetes Therapy - June 8, 2023 Category: Endocrinology Source Type: research